Solventum Corporation (SOLV) Guidance & Earnings Results

On 2026-08-05 Solventum Corporation raised guidance: "FY2026 organic sales growth raised to +2.5% to +3.0% from +2.0% to +3.0%; adjusted EPS raised to $7.10-$7.20 from upper end of $6.40-$6.60; free cash flow raised to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SOLVSolventum CorporationFollow SOLV — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 14.5B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Raised	FY2026 organic sales growth raised to +2.5% to +3.0% from +2.0% to +3.0%; adjusted EPS raised to $7.10-$7.20 from upper end of $6.40-$6.60; free cash flow raised to $200M-$300M · full year
5 May 26	Reaffirmed	Organic sales growth +2-3%; adjusted EPS toward high end of $6.40-6.60; FCF ~$200M. · full year
26 Feb 26	Raised	FY2026 organic sales growth +2-3%, adjusted EPS $6.40-$6.60, FCF ~$200M · full year
6 Nov 25	Raised	Full-year adjusted EPS raised to $5.98-$6.08 from $5.88-$6.03; organic sales growth raised to high end of 2-3% · full year
7 Aug 25	Raised	FY2025 organic sales growth raised to +2.0% to +3.0% from +1.5% to +2.5%; FY2025 adjusted EPS raised to $5.80 to $5.95 from $5.45 to $5.65; FY2025 free cash flow unchanged at $450M to $550M · full year

Solventum Corporation — questions

What guidance did Solventum Corporation give?: On 2026-08-05: "FY2026 organic sales growth raised to +2.5% to +3.0% from +2.0% to +3.0%; adjusted EPS raised to $7.10-$7.20 from upper end of $6.40-$6.60; free cash flow raised to $200M-$300M"
When does Solventum Corporation report earnings?: Solventum Corporation's next earnings report is expected on 2026-11-05.

Every figure on this page comes from Solventum Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.